Finerenone, Bayer’s selective mineralocorticoid receptor antagonist (MRA), has been shown to reduce the risk of new-onset atrial fibrillation (AFib) and atrial flutter (AFL) in patients with cardiovascular-kidney-metabolic (CKM) syndrome, according to a recent pooled analysis published in the Journal of the American College of Cardiology.
Study Overview CKM syndrome encompasses patients with cardiovascular issues, kidney disease, diabetes, or metabolic diseases. While finerenone’s benefits in chronic kidney disease (CKD) and type 2 diabetes (T2D) patients have been documented, its impact on AFib and AFL risk across the broader CKM spectrum was unclear. To address this, researchers analyzed data from three clinical trials: FIDELIO-DKD and FIGARO-DKD (focused on CKD and T2D patients) and FINEARTS-HF (including heart failure patients). The final analysis included more than 14,000 patients, with results showing significant differences between those treated with finerenone and those on a placebo.
Key Findings During a median follow-up of nearly three years, 4.3% of patients developed new-onset AFib or AFL. Of those treated with finerenone, 3.9% experienced these conditions, compared to 4.7% in the placebo group, demonstrating a clear benefit of the treatment. This risk reduction was consistent even among patients with specific conditions like CKD or T2D.
Researchers also noted that patients who developed AFib or AFL had a substantially higher risk of adverse cardiovascular events, kidney complications, and hospitalization for heart failure. These findings underscore the importance of finerenone in mitigating these risks and improving patient outcomes across the CKM spectrum.
Conclusion The study highlights finerenone’s potential to not only reduce the incidence of AFib and AFL but also to improve overall cardiovascular and kidney outcomes for patients with CKM syndrome. This supports its broader use in managing patients with complex comorbidities.
Follow MEDWIRE.AI for updates on cardiovascular and kidney disease treatments.
